Phase II Double Blinded, Placebo-Controlled, Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered with Omalizumab, an Anti-IgE mAb

-
Investigator: Jeffrey A. Bluestone, PhD
Sponsor: Genentech, Inc.

Location(s): United States

Description

no description available